A Major Setback: FDA Halts uniQure's Huntington's Gene Therapy Trial

The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor

GSK's Bold Move: A $1.8 Billion Bet on the Future of Pulmonary Hypertension Treatment

The Grand Ambition of Early Cancer Detection: Unpacking Tests Like Galleri

A Looming Showdown: Can RFK Jr. and Dr. Maha Force the FDA to Confront the Ultra-Processed Food Crisis?

The Shifting Tides of American Health: What's Next for HHS Post-2026?

A Game-Changer on the Horizon: Disc Medicine's Bitopertin and the FDA's Looming Decision

Unpacking Trump's Vision for 340B: A Pilot Program's Complex Ripples

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

Unlocking New Frontiers: How Revolution Medicines and Merck Are Redefining the Cancer Fight

Alnylam's Ambitious Five-Year Vision: Betting Big on Amvuttra and Beyond

The Evolving Landscape of Pharma and Biotech Employment

Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push

Cytokinetics' Myqorzo Secures Landmark FDA Approval, Reshaping HCM Treatment Landscape

Navigating the Complex Currents of Modern Pharmaceuticals

The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices

ASH 2025: Glimmers of Hope and Big Strides in Blood Disorders

A Glimmer of Hope: Syndax's Novel AML Drug Shines Bright at ASH Meeting

A New Dawn in Cancer Detection: Freenome's Bold Move Towards Public Markets

Unpacking Pharma's Future: Costs, Generics, and the Tug-of-War for Access

Unlocking Affordable Medicine: A Call for Smarter Biosimilar Regulation

A Noteworthy Platform: Vaccine Critic Aaron Siri Addresses the ACIP

The Pharmaceutical Pulse: A Year-End Reflection on Innovation, Politics, and Public Trust in 2025

The Anticipation Builds: ASH 2025 and the Evolving Landscape of Blood Cancer Therapies

The Looming Shadow Over American Science: A Critical Look at Funding Threats

A Glimmer of Hope for Hair Loss Sufferers: Cosmo Pharma's Breezula Delivers in Landmark Trial

A Notable Shift: Dr. Theresa Michele Steps Down from FDA's Nonprescription Drug Leadership

A Beacon of Hope: Capricor's Cell Therapy Shows Remarkable Heart Improvements in Duchenne Patients

The Quest for Immortality: Billions Bet on Beating Time Itself

The Silent Crisis: A New Fight for Independent Doctors

Pharma's Unfolding Drama: 340B Clashes, Vaccine Progress, and Cancer Innovation

The Fight for Affordable Medicine: Hospitals Take On 340B Program Changes

The Unexpected Halt: CMS Pulls Plug on Kidney Care Experiment Two Years Early

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

A New Hope for Kidney Disease Patients? FDA Greenlights Voyxact, But Pricing Questions Linger

A New Era for Biotech: Landmark Commission Calls for Radical Research Funding Overhaul

Donald Trump's Evolving Healthcare Stance: A Surprising Twist for the ACA